Gustavo dos Santos Fernandes

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy

Andrea Cercek, Gustavo dos Santos Fernandes, Campbell S.D. Roxburgh et al. · Clinical Cancer Research · 2020 · 247 citations

Medicine, Molecular Genetics, Oncology +17

A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers

Andrea Cercek, Walid K. Chatila, Rona Yaeger et al. · JNCI Journal of the National Cancer Institute · 2021 · 195 citations · Full text

Medicine, Oncology, Pathology +7

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Gustavo dos Santos Fernandes, Daniel M. Girardi, João Paulo Giacomini Bernardes et al. · BMC Cancer · 2018 · 82 citations · Full text

Veterinary Medicine, Oncology, Surgery +14

Cancer Deaths due to Lack of Universal Access to Radiotherapy in the Brazilian Public Health System

Lucas C. Mendez, Fábio Ynoe de Moraes, Gustavo dos Santos Fernandes et al. · Clinical Oncology · 2017 · 64 citations · Full text

Medicine, Oncology, Radiation Oncology +8